TB-500 (Thymosin Beta-4) vs. ARA-290

When evaluating TB-500 (Thymosin Beta-4) versus ARA-290 for biological age reduction, the primary consideration is the specific hallmark of aging being targeted. While both compounds offer systemic healthspan benefits, their mechanisms of action are distinct.

When to prioritize TB-500 (Thymosin Beta-4):

Select TB-500 (Thymosin Beta-4) when the primary clinical objective aligns with its core mechanism: upregulates actin to promote cell migration, angiogenesis, and systemic tissue repair.. This is particularly relevant for protocols focused on systemic tissue regeneration, flexibility support, and wound healing..

When to prioritize ARA-290:

Conversely, ARA-290 is the superior choice when targeting non-hematopoietic epo analog that activates the innate repair receptor (irr) to reduce inflammation and protect tissue., making it the preferred agent for tissue protection, neuropathy relief, and anti-inflammatory action..